Showing 3007 results
-
Story /Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.
-
Event / Oct 23, 2026At the European Society for Medical Oncology (ESMO) Congress 2026, we will present the latest data from our oncology portfolio, demonstrating our ongoing commitment to driving progress in cancer…
-
Clinical Trials /
-
Biography /
-
Story /Novartis has reached the highest performance tier in the CCLA Corporate Mental Health Benchmark, recognizing a comprehensive approach to workplace mental health, wellbeing and employee support.
-
Biography /
-
Story /Novartis is working with community partners to bring heart disease and cancer screening, information and support closer to where people are.
-
Press release /In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible…
-
Press release /Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 301
- › Next page